HWGB Biotech aims to provide a comprehensive range of big health products and solutions that adopts a preventive measure readily available to give a peace of mind of many around the world.
Backed by a panel of experienced consultants with relevant experience in the healthcare and technology industry in regards to matters involving healthcare and biotechnology.
KUALA LUMPUR, 9 JUNE 2021 – Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601), through its wholly-owned subsidiary HWGB Biotech Sdn Bhd (“HWGB Biotech”), today entered into an agreement with Propharm (M) Sdn. Bhd. (“Propharm”) to supersede and to set out further details of the previous MOU signed on 28 May 2021. HWGB earlier had signed a MOU with Propharm to be the exclusive Sub-distributor of Bivalent Oral Poliomyelitis Vaccine Type I and III (“Polio Vaccine”) in Malaysia after the vaccine official arrival into the country.
The Agreement has been made to enable HWGB and Propharm to further set out the agreed terms and conditions in relation to earlier MOU. Hence, Propharm officially appoints HWGB Biotech as the exclusive sub-distributor of Polio Vaccine.
Executive Director of HWGB, Mr Bernard Lim Wee Kiat expressed: “We are delighted to be officially appointed by Propharm as the exclusive sub-distributor of the Polio Vaccine in Malaysia. We are looking to play a part in improving the public’s well-being and their wellness to prevent poliomyelitis (Polio). Hence, once we have received the imported vaccines, we will be able to expedite the distribution of the vaccine to the public.
***
HWGB BIOTECH SDN BHD (Formerly known as HWG Consortium Sdn Bhd) [Company Number: 201201022032 (1006524-T)]
2020 HWGB Biotech. All rights Reserved.